Advancing new drug therapies for unmet medical needs

Developing novel drug therapies for unmet medical needs 2018-11-14T18:17:53+00:00

The Dimerix Limited Clinical Trials – ACTION for Diabetic Kidney Disease and ACTION for Focal Segmental Glomerulosclerosis – Are Now Open!

Click Here For More Information

Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)

Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs

Research

Our lead program DMX-200 is advancing through Phase 2 trials in patients with Chronic Kidney Disease (CKD).

Learn More

Technology

Our Receptor Heteromer Investigation Technology (Receptor-HIT) has been used by global pharmaceutical partners, and supported the development of our own DMX-200 program.

Learn More

Investors

Access the latest company news and information

Visit Investor Centre

Recent news and media

ASX: Dimerix Receives Orphan Drug Designation In The European Union For DMX-200 In FSGS

  Read the release here.

ASX: DIMERIX DOSES FIRST PATIENT IN DMX-200 CLINICAL TRIAL FOR DIABETIC KIDNEY DISEASE

Read more here.

2018 CEO’s AGM presentation – investor call recording

Dr Nina Webster, CEO of Dimerix, presented to shareholders at the 2018 AGM where she provided a review of key highlights [...]

Click here to view analyst coverage
Click here to view our corporate fact sheet
Click here to view our corporate presentation

Home
Company
Program
Technology
Investors
Contact

© Copyright 2018 Dimerix | Credits

subscribe to patient updates

subscribe to news updates